Gene

PREX2

phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2

Explore in graph →CI-GENE-00020945HGNC:22950 ENSG00000046889 NCBI 80243 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600K + PREX2 R172IBRAF PREX21
Vemurafenib	Melanoma	Predictive	C	Supports Resistance	2	accepted	EID6268 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E/K (known BRAF inhibitor sensitizing mutations), PREX2 R172I was associated with a case of acquired resistance to BRAF inh… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (162)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved162 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Esophageal Carcinoma (TCGA, Firehose Legacy) esca_tcga	Esophageal Adenocarcinoma	Ssm	15	185	8.1%

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
· Cancer Discov · 2014 · PMID 24265155 · validated civic_curation pubmed